ANGIOTENSIN II RECEPTOR ANTAGONIST FOR PREVENTION OR TREATMENT OF SYSTEMIC DISEASES IN CATS

• Main Authors: SENT ULRIKE, LANG INGO, STARK MARCUS
• Format: Patent
• Language: English; Japanese
• Published: 26.05.2016
• Subjects: HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS

PROBLEM TO BE SOLVED: To provide a new drug for prevention or treatment of systemic diseases in cats, e.g., cardiovascular diseases, such as dilated cardiomyopathy (DCM), mitral valve insufficiency (MI), hypertrophic cardiomyopathy (HCM) and other acquired or hereditary heart diseases, systemic hypertension, e.g., hypertension associated with renal diseases, chronic renal failure and other vascular diseases, and metabolic disorders like diabetes mellitus.SOLUTION: A pharmaceutical composition comprises angiotensin II receptor 1 (AT-1) antagonist (sartan). A therapeutically effective amount of AT-1 antagonist (sartan) is about 0.01 to about 5.0 mg/kg of body weight.SELECTED DRAWING: None 【課題】ネコの全身性疾患、例えば拡張型心筋症(DCM)、僧帽弁閉鎖不全(MI)、肥大型心筋症(HCM)及び他の後天的又は先天的心疾患のような循環器系疾患、全身性高血圧、例えば腎疾患に付随する高血圧、慢性腎疾患及び他の血管性疾患、真性糖尿病のような代謝性疾患の新予防又は治療薬の提供。【解決手段】アンジオテンシンII受容体1(AT-1)アンタゴニスト(サルタン)を含む医薬組成物。治療有効量のＡＴ−１アンタゴニスト（サルタン）が約０．０１〜約５．０ｍｇ／ｋｇ体重である。【選択図】なし